アルツハイマー型認知症治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 21

2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25

3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Disease Staging Systems 38
3.3 Symptoms 41
3.4 Prognosis 43
3.5 Quality of Life 43

4 Epidemiology 45
4.1 Disease Background 45
4.2 Risk Factors and Comorbidities 46
4.2.1 A family history of Alzheimer’s increases the risk of developing the disease by 7.5 times 47
4.2.2 The APOE ε4 allele triples the risk for AD 48
4.2.3 Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life 48
4.2.4 The incidence and prevalence of AD double every five years after age 65 years 49
4.2.5 Diabetes doubles the risk of AD in men, but only marginally affects the risk in women 49
4.2.6 Women are 1.5 times more likely to develop AD than men 50
4.2.7 Depression triples the risk for AD, and is the most common comorbidity 50
4.2.8 Up to 70% of AD patients also suffer from anxiety 51
4.2.9 Psychosis and agitation are common comorbidities in Alzheimer’s patients 51
4.3 Global Trends 51
4.3.1 US 52
4.3.2 5EU 53
4.3.3 Japan 55
4.3.4 China 56
4.3.5 India 56
4.4 Forecast Methodology 57
4.4.1 Sources Used 62
4.4.2 Forecast Assumptions and Methods 69
4.4.3 Sources Not Used 79
4.5 Epidemiology Forecast (2013-2023) 81
4.5.1 Total Prevalent Cases of AD 81
4.5.2 Age-Specific Total Prevalent Cases of AD 83
4.5.3 Sex-Specific Total Prevalent Cases of AD 85
4.5.4 Age-Standardized Total Prevalence of AD 88
4.5.5 Total Prevalent Cases of AD, by Severity 89
4.5.6 Total Prevalent Cases of MCI 91
4.5.7 Age-Specific Total Prevalent Cases of MCI 93
4.5.8 Sex-Specific Total Prevalent Cases of MCI 95
4.5.9 Age-Standardized Total Prevalence of MCI 98
4.6 Discussion 99
4.6.1 Conclusions Regarding the Epidemiological Trends 99
4.6.2 Limitations of the Analysis 101
4.6.3 Strengths of the Analysis 102

5 Disease Management 103
5.1 Diagnosis Overview 103
5.1.1 Probable AD Dementia 106
5.1.2 Preclinical AD 107
5.1.3 MCI 108
5.2 Treatment Overview 110
5.3 Clinical Practice 112
5.3.1 Leading Prescribed Therapies 114
5.4 US 115
5.5 France 118
5.6 Germany 120
5.7 Italy 122
5.8 Spain 124
5.9 UK 126
5.10 Japan 129
5.11 China 131
5.12 India 133

6 Competitive Assessment 135
6.1 Overview 135
6.2 Product Profiles – Major Brands 136
6.2.1 Aricept (donepezil hydrochloride) 136
6.2.2 Exelon (rivastigmine, rivastigmine tartrate) 141
6.2.3 Razadyne (galantamine hydrobromide) 146
6.2.4 Namenda (memantine hydrochloride) 151
6.3 Other Drugs/Classes 157

7 Unmet Need and Opportunity 159
7.1 Overview 159
7.2 Drugs with Disease-Modifying Mechanisms of Action 160
7.2.1 Unmet Need 160
7.2.2 Gap Analysis 161
7.2.3 Opportunity 162
7.3 Diagnosis in the Prodromal or Presymptomatic Stages 163
7.3.1 Unmet Need 163
7.3.2 Gap Analysis 164
7.3.3 Opportunity 165
7.4 Improved Control of Symptoms 166
7.4.1 Unmet Need 166
7.4.2 Gap Analysis 167
7.4.3 Opportunity 168
7.5 Easier Access to Treatment 169
7.5.1 Unmet Need 169
7.5.2 Gap Analysis 169
7.5.3 Opportunity 170

8 Pipeline Assessment 172
8.1 Overview 172
8.2 Clinical Trial Mapping 173
8.2.1 Clinical Trials by Class 173
8.3 Promising Drugs in Clinical Development 174
8.3.1 Biopharmaceutical Products 176
8.3.2 Small Molecule 201
8.3.3 Other Drugs in Development 249

9 Current and Future Players 252
9.1 Overview 252
9.2 Trends in Corporate Strategy 253
9.3 Company Profiles 254
9.3.1 Actavis 254
9.3.2 Lundbeck 256
9.3.3 Eisai 260
9.3.4 Pfizer 262
9.3.5 Novartis 264
9.3.6 Roche 266
9.3.7 Eli Lilly 268
9.3.8 Merck & Co. 271
9.3.9 AstraZeneca 273
9.3.10 Takeda 275

10 Market Outlook 278
10.1 Global Markets 278
10.1.1 Forecast 278
10.1.2 Drivers and Barriers – Global Issues 285
10.2 United States 288
10.2.1 Forecast 288
10.2.2 Key Events 292
10.2.3 Drivers and Barriers 293
10.3 France 296
10.3.1 Forecast 296
10.3.2 Key Events 299
10.3.3 Drivers and Barriers 299
10.4 Germany 302
10.4.1 Forecast 302
10.4.2 Key Events 305
10.4.3 Drivers and Barriers 305
10.5 Italy 307
10.5.1 Forecast 307
10.5.2 Key Events 311
10.5.3 Drivers and Barriers 311
10.6 Spain 313
10.6.1 Forecast 313
10.6.2 Key Events 316
10.6.3 Drivers and Barriers 316
10.7 United Kingdom 318
10.7.1 Forecast 318
10.7.2 Key Events 321
10.7.3 Drivers and Barriers 322
10.8 Japan 324
10.8.1 Forecast 324
10.8.2 Key Events 328
10.8.3 Drivers and Barriers 328
10.9 China 330
10.9.1 Forecast 330
10.9.2 Key Events 334
10.9.3 Drivers and Barriers 334
10.10 India 336
10.10.1 Forecast 336
10.10.2 Key Events 339
10.10.3 Drivers and Barriers 339

11 Appendix 342
11.1 Bibliography 342
11.2 Abbreviations 367
11.3 Methodology 377
11.4 Forecasting Methodology 377
11.4.1 Diagnosed AD Patients 377
11.4.2 Percent Drug-Treated Patients 378
11.4.3 Drugs Included in Each Therapeutic Class 378
11.4.4 Launch and Patent Expiry Dates 379
11.4.5 General Pricing Assumptions 380
11.4.6 Compliance Assumptions 381
11.4.7 Individual Drug Assumptions 383
11.4.8 Generic Erosion 389
11.4.9 Pricing of Pipeline Agents 389
11.5 Primary Research – KOLs Interviewed for This Report 390
11.6 Primary Research – Prescriber Survey 391
11.7 About the Authors 392
11.7.1 Analyst 392
11.7.2 Therapy Area Director 392
11.7.3 Epidemiologist 393
11.7.4 Global Head of Healthcare 393
11.8 About GlobalData 394
11.9 Disclaimer 394